Hongyun Gao1, Juanjuan Han1, Guoping Li2, Wenjing Zhang1. 1. Special Inspection Department, Dongying City People's Hospital Dongying, China. 2. Department of Cardiology, Dongying City People's Hospital Dongying, China.
Abstract
OBJECTIVE: To investigate the effects of rosuvastatin combined with clopidogrel bisulfate on blood lipids, cardiac function, and inflammatory factor levels in elderly patients with coronary heart disease (CHD). METHODS: A total of 100 elderly patients with CHD treated in our hospital from January 2018 to January 2020 were retrospectively selected and assigned to the control group (n=50) and the observation group (n=50) according to different types of medications. The control group was treated with clopidogrel bisulfate, while the observation group was treated with clopidogrel bisulfate combined with rosuvastatin. T1, T2, T3, and T4, which indicated 5, 10, 15, and 20 days after medication respectively, were set up to observe the changes of relevant indexes in the two groups after medication. The changes in blood lipids, cardiac function, and inflammatory factors were compared between the two groups. RESULTS: The clinical efficacy of the observation group was superior to the control group (P<0.05). No significant differences were determined in the levels of TC and LDL-C at T1 and T2 between the two groups (P>0.05); however, the observation group obtained lower TC and LDL-C levels than the control group at T3 and T4 (P<0.05). The levels of hs-CRP, TNF-α, BNP and NT-proBNP were not significantly different between the two groups at T1 and T2 (P>0.05), and lower levels of hs-CRP, TNF-α, BNP and NT-proBNP were observed in the observation group than in the control group at T3 and T4 (P<0.05). The two groups presented no significant differences in the left ventricular ejection fraction (LVEF) level and the Wall Motion Score Index (WMSI) score (P>0.05). After treatment, the observation group scored higher in the LVEF level and lower in the WMSI score than the control group (both P<0.05). The adverse reaction rate of the two groups was similar (P>0.05). CONCLUSION: Rosuvastatin combined with clopidogrel bisulfate is effective in the treatment of elderly patients with CHD, which can effectively improve the cardiac function of patients and reduce the levels of blood lipids and inflammatory factors. AJTR
OBJECTIVE: To investigate the effects of rosuvastatin combined with clopidogrel bisulfate on blood lipids, cardiac function, and inflammatory factor levels in elderly patients with coronary heart disease (CHD). METHODS: A total of 100 elderly patients with CHD treated in our hospital from January 2018 to January 2020 were retrospectively selected and assigned to the control group (n=50) and the observation group (n=50) according to different types of medications. The control group was treated with clopidogrel bisulfate, while the observation group was treated with clopidogrel bisulfate combined with rosuvastatin. T1, T2, T3, and T4, which indicated 5, 10, 15, and 20 days after medication respectively, were set up to observe the changes of relevant indexes in the two groups after medication. The changes in blood lipids, cardiac function, and inflammatory factors were compared between the two groups. RESULTS: The clinical efficacy of the observation group was superior to the control group (P<0.05). No significant differences were determined in the levels of TC and LDL-C at T1 and T2 between the two groups (P>0.05); however, the observation group obtained lower TC and LDL-C levels than the control group at T3 and T4 (P<0.05). The levels of hs-CRP, TNF-α, BNP and NT-proBNP were not significantly different between the two groups at T1 and T2 (P>0.05), and lower levels of hs-CRP, TNF-α, BNP and NT-proBNP were observed in the observation group than in the control group at T3 and T4 (P<0.05). The two groups presented no significant differences in the left ventricular ejection fraction (LVEF) level and the Wall Motion Score Index (WMSI) score (P>0.05). After treatment, the observation group scored higher in the LVEF level and lower in the WMSI score than the control group (both P<0.05). The adverse reaction rate of the two groups was similar (P>0.05). CONCLUSION: Rosuvastatin combined with clopidogrel bisulfate is effective in the treatment of elderly patients with CHD, which can effectively improve the cardiac function of patients and reduce the levels of blood lipids and inflammatory factors. AJTR
Authors: Thimo Marcin; Prisca Eser; Eva Prescott; Nicolai Mikkelsen; Leonie F Prins; Evelien K Kolkman; Óscar Lado-Baleato; Carmen Cardaso-Suaréz; Wendy Bruins; Astrid E van der Velde; Carlos Peña Gil; Marie Christine Iliou; Diego Ardissino; Uwe Zeymer; Esther P Meindersma; Arnoud Wj Van't Hof; Ed P de Kluiver; Matthias Wilhelm Journal: Eur J Prev Cardiol Date: 2019-12-18 Impact factor: 7.804
Authors: Joy Van de Cauter; Dirk De Bacquer; Els Clays; Delphine De Smedt; Kornelia Kotseva; Lutgart Braeckman Journal: Eur J Prev Cardiol Date: 2019-04-10 Impact factor: 7.804
Authors: Pablo Catalan-Serra; Francisco Campos-Rodriguez; Nuria Reyes-Nuñez; Maria Jose Selma-Ferrer; Cristina Navarro-Soriano; Marta Ballester-Canelles; Juan-José Soler-Cataluña; Pilar Roman-Sanchez; Carmen V Almeida-Gonzalez; Miguel A Martinez-Garcia Journal: Stroke Date: 2019-02 Impact factor: 7.914
Authors: Dan Jiang; Min Sun; Linna You; Kai Lu; Lei Gao; Chunxiao Hu; Shiyong Wu; Guanglei Chang; Hongmei Tao; Dongying Zhang Journal: Life Sci Date: 2019-03-10 Impact factor: 5.037